

REMARKS

Claims 18-43 are active. Page 1 of the specification has been amended to recite continuity information.

SUPPORT FOR THE AMENDMENT

Claims 18-24, directed to nucleic acids, find support in the original claims, especially Claims 4-7. The hybridization conditions recited by Claims 18, 38 and 42 are described in the specification on page 6, lines 3 and 4. Claim 23 also finds support in the specification on page 6, lines 7-13 and page 12, lines 8-25. Support for vector Claims 25 and 26 is found in original Claim 8 and in the specification on page 12, lines 8-16. Support for Claims 27-34, directed to host cells, is found in original Claims 9 and 10 and in the specification on page 6, lines 14-18 and on page 12, see e.g., lines 4, 5, and 17. Claims 35-37, directed to methods for making a polypeptide, find support in original Claim 11. Claims 38-41 directed to antibodies, find support in original Claims 12-15. Claim 41 also finds support in the specification at page 20, lines 6-11. Claims 42 and 43 find support in original Claims 16 and 17. Accordingly, the Applicants do not believe that any new matter has been added.

CONCLUSION

The Applicants submit that this application is now ready for an early examination on the merits. Favorable consideration is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Attorney of Record
Registration No. 24,618



22850

(703) 413-3000
NFO:TMC:krs

A handwritten signature in black ink, appearing to read "Thomas Cunningham".

Thomas M. Cunningham, Ph.D.
Registration No. 45,394